drugset
drugset / Trial / NCT00548249

Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis

NCT00548249 ↗

Phase 2 Completed 131 enrolled Rockwell Medical Technologies, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether Dialysate containing soluble iron (Soluble Ferric Pyrophosphate) is safe and effective in maintaining physiological iron levels during chronic hemodialysis.

Timeline

Start
2007-08
Primary completion
2009-10
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Triferic Other / unclassified 5 ug Other
Subject Triferic Other / unclassified 10 ug Other
Subject Triferic Other / unclassified 12 ug Other
Subject Triferic Other / unclassified 15 ug Other

Indications

end stage renal failure